You are here

Home › Listings › Life Sciences › Orion Nutraceuticals Inc.

Orion Nutraceuticals Inc.

Orion Nutraceuticals Inc.
Listing Exchange: 
CSE
Status: 
Halted Pending Fundamental Change
Industry: 
Life Sciences
Symbol: 
ORI
CSE Index: 
Currency: 

Orion Nutraceuticals Inc. produces and develops innovative products with key strategic partners in the cannabis life science industry. In conjunction with its professional sports strategic alliances, the company intends to advance research and development in the plant science sector, deliver science-based products and services, and market CBD therapies to the mainstream with proprietary brands and products.

You are here

Home

Orion Nutraceuticals Inc. (ORI)

SEDAR Information

Search form

Company Info

Address
Suite 1890 – 1075 West Georgia Street
Vancouver, BC V6E 3C9
Canada
Phone
604-687-2038
Fax
604-687-3141
Email
info@orionnutra.ca
Website
http://www.orionnutra.ca
Listing date
Wednesday, October 17, 2018
Transfer Agent
Endeavor Trust Corporation

Capitalization

Issued & Outstanding: 
29307965
Reserved for Issuance: 
38000

Company Officers

Joel Dumaresq, Chief Executive Officer
Guy Bourgeois, Director
Amanda Boudreau, Director

News Releases

13/03/2024

Orion Nutraceuticals Announces Management Changes

07/06/2023

Orion Nutraceuticals Announces Appointment of Directors

Bulletins

20/05/2020

2020-0530 – Consolidation - Orion Nutraceuticals Inc. (ORI)

le 20 mai/May 2020

Orion Nutraceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidation common shares for every twenty five (25) pre-consolidation common shares.

As a result, the outstanding shares of the company will be reduced to approximately 1,993,282 common shares.

The name and symbol will not change.

CSE Filings

Form 7 - Monthly Progress Report - April 2024

Form 5 - Quarterly Listing Statement - Interim Period Ended February 29, 2024

CFO Certificate - Period Ended February 29, 2024

CEO Certificate - Period Ended February 29, 2024

MD&A - Period Ended February 29, 2024